Stockreport

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma [Yahoo! Finance]

Citius Pharmaceuticals, Inc.  (CTXR) 
NASDAQ:AMEX Investor Relations: ir.citiuspharma.com
PDF Minnesota (UMN) Masonic Cancer Center's ongoing Phase 1 trial to determine the maximum tolerated dose of LYMPHIR plus CAR-T therapy CRANFORD, N.J. April 11, 2024 /PRNe [Read more]